Sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial). This is an ASCO ...
Stage 1 multiple myeloma features low beta-2 microglobulin, high albumin, and no organ damage, often detected incidentally. Diagnosis involves blood, urine, imaging tests, and bone marrow biopsy to ...
Minimal residual disease (MRD) negativity (neg) in patients (pts) with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs ...
A dexamethasone-sparing regimen of daratumumab and lenalidomide was safe and effective in older, frail patients with newly diagnosed multiple myeloma. Among that select group of patients, ...
The addition of subcutaneous daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy had a significant benefit on progression-free survival among ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results